Read the source behind the answer

Find the question in the source

Begin with the claim you want to check. Is it about who can provide care, whether a product is approved, what compounding means, or how a problem can be reported? Choose the source for that question. A page about drug status does not decide which treatment fits your own injury.

The links below collect further reading for the guide. Open the original page with the claim in front of you. Read the page’s date, scope, and limits as well as the headline.

• Keep the product or professional name precise.
• Look at the scope and date of the source.
• Separate what it says from what you infer.

Check compounding and product status

FDA, the Food and Drug Administration, handles federal drug review. Compounding means preparing a medicine instead of supplying a manufacturer’s finished drug.

As of September 2026, FDA states that compounded medicines are not approved and do not undergo its checks before sale for effectiveness, quality, or safety.

The compounding question-and-answer page describes that distinction and the roles involved in preparation. The bulk-substance page concerns ingredients considered for compounding. It is different from a source establishing the approval of a finished drug product.

The FDA safety page keeps warnings beside ingredients whose compounding requests were taken back. Its content date is April 22, 2026, and it gives no date for each withdrawn request.

FDA approval does not follow from taking a request back. Nor does that action add the peptide to FDA’s ingredient list for compounding.

In a draft policy published October 30, 2026, the U.S. Department of Health and Human Services (HHS) said its intent is to take no enforcement action against pharmacies and physicians with state licenses that meet all its conditions to compound BPC-157 alone or TB-500 alone for an individual patient’s prescription, never a blend; this is not FDA approval, and neither peptide is on FDA’s 503A bulks list.

• Ask whether a statement concerns an ingredient or a finished product.
• Keep how the medicine is taken, such as by injection or by mouth, attached to the claim.
• Do not turn an absent approval into a complete answer about compounding.

Follow a name to a board record

The medical boards' federation directory points to state and territorial doctor licensing boards.

The pharmacy boards' association maintains a separate directory for boards that license pharmacies.

FDA's BeSafeRx page links readers to state pharmacy license searches.

Use those routes to reach the actual board record. The names and current details come from that record, not from this guide. If the professional has a different kind of license, ask which board holds it before choosing a lookup.

• Match the person or pharmacy you were actually given.
• Read the board's status description in full.
• Keep questions about the proposed care open after the check.

Read remote-care policy in context

The federation's telemedicine policy describes professional standards and location-based permission to practice, while enforceable requirements come from the states.

Its May 2026 prescribing guidance says choosing a treatment on a website is not enough for care. It also calls for patients’ further questions to reach the health professional.

Those documents help frame questions about an online visit. They do not provide a live assessment of a service you found. Ask the service how its process works and how it handles a concern that needs information beyond the remote exchange.

• Distinguish model guidance from a binding state rule.
• Ask about the state where the appointment will take place.
• Keep the requirement for a proper assessment attached to remote-care statements.

Read about reactions and product problems

FDA's MedWatch program accepts medicine-problem reports from consumers as well as health professionals.

FDA’s online report page is called a dashboard. Its cautions say that a report cannot prove a medicine was the cause. The reports also cannot show how common the problem is.

The product concerns chapter brings the urgent-help reading together. Reading about a reported concern cannot assess what is happening in your own case. Keep a personal concern in the care conversation, and use the relevant reporting route when you want to describe a product problem.

• Read the limits beside any reported event.
• Ask a health professional about personal symptoms.
• Keep source reading separate from self-directed treatment instructions.